The race to launch a respiratory syncytial virus (RSV) vaccine for adults in the U.S. intensified today as the U.S. Food and Drug Administration (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted that the available data support the safety and effectiveness of GSK Inc.' AREXVY™ (RSVPreF3 OA).
The VRBPAC voted 12-0 on effectiveness and 10-2 on safety.
This is very positive news since RSV vaccines are not currently approved anywhere in the world.
Read More
